ES551005A0 - Un procedimiento para preparar derivados de tironina - Google Patents

Un procedimiento para preparar derivados de tironina

Info

Publication number
ES551005A0
ES551005A0 ES551005A ES551005A ES551005A0 ES 551005 A0 ES551005 A0 ES 551005A0 ES 551005 A ES551005 A ES 551005A ES 551005 A ES551005 A ES 551005A ES 551005 A0 ES551005 A0 ES 551005A0
Authority
ES
Spain
Prior art keywords
hydrogen
4alkyl
hydroxy
tyronine
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES551005A
Other languages
English (en)
Other versions
ES8800157A1 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Smith Kline & French Laboratories Ltd
Original Assignee
Smith Kline & French Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smith Kline & French Laboratories Ltd filed Critical Smith Kline & French Laboratories Ltd
Publication of ES551005A0 publication Critical patent/ES551005A0/es
Publication of ES8800157A1 publication Critical patent/ES8800157A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/673—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by change of size of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
    • C07C45/71—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/12—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
ES551005A 1985-01-18 1986-01-17 Un procedimiento para preparar derivados de tironina Expired ES8800157A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB858501372A GB8501372D0 (en) 1985-01-18 1985-01-18 Chemical compounds

Publications (2)

Publication Number Publication Date
ES551005A0 true ES551005A0 (es) 1987-11-01
ES8800157A1 ES8800157A1 (es) 1987-11-01

Family

ID=10573093

Family Applications (1)

Application Number Title Priority Date Filing Date
ES551005A Expired ES8800157A1 (es) 1985-01-18 1986-01-17 Un procedimiento para preparar derivados de tironina

Country Status (24)

Country Link
US (3) US4766121A (es)
EP (1) EP0188351B1 (es)
JP (1) JPH07103070B2 (es)
KR (1) KR930011302B1 (es)
CN (1) CN1010310B (es)
AT (1) ATE61581T1 (es)
AU (1) AU577917B2 (es)
CA (1) CA1319148C (es)
DE (1) DE3678000D1 (es)
DK (1) DK164592C (es)
ES (1) ES8800157A1 (es)
FI (1) FI860229A7 (es)
GB (1) GB8501372D0 (es)
GR (1) GR860122B (es)
HU (1) HU194807B (es)
IE (1) IE58867B1 (es)
IL (1) IL77605A (es)
JO (1) JO1439B1 (es)
NO (1) NO860159L (es)
NZ (1) NZ214843A (es)
PH (1) PH22691A (es)
PT (1) PT81844B (es)
ZA (1) ZA86319B (es)
ZW (1) ZW886A1 (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8501372D0 (en) * 1985-01-18 1985-02-20 Smith Kline French Lab Chemical compounds
US5371284A (en) * 1987-09-03 1994-12-06 Schering Corporation Phenyl acetylenic acetals
US5284971A (en) * 1992-07-16 1994-02-08 Syntex (U.S.A.) Inc. 4-(3-cyclohexyl-4-hydroxy or-methoxy phenylsulfonyl) 3,5 dibromo phenyl acetic thyromimetic cholesterol-lowering agents
EP0580550B1 (en) * 1992-07-21 1997-10-22 Novartis AG Oxamic acid derivatives as hypocholesteremic agents
GB9401891D0 (en) * 1994-02-01 1994-03-30 Boots Co Plc Therapeutic agents
US5622948A (en) * 1994-12-01 1997-04-22 Syntex (U.S.A.) Inc. Pyrrole pyridazine and pyridazinone anti-inflammatory agents
JPH11510479A (ja) * 1995-06-07 1999-09-14 ネオルックス コーポレイション タモキシフェン類似体による心臓血管疾病の予防及び治療
DE69636677D1 (de) 1995-12-13 2006-12-14 Univ California Kristalle der mit einem Ligand komplexierten Ligandenbindedomäne des Schilddrüsenhormonrezeptors
US6266622B1 (en) * 1995-12-13 2001-07-24 Regents Of The University Of California Nuclear receptor ligands and ligand binding domains
US5883294A (en) * 1997-06-18 1999-03-16 The Regeants Of The University Of California Selective thyroid hormone analogs
PT1157001E (pt) 1999-03-01 2004-10-29 Pfizer Prod Inc Acidos oxamicos e derivados como ligandos do receptor da tiroide
EP1033364B1 (en) 1999-03-01 2005-02-23 Pfizer Products Inc. Cyano containing oxamic acids and derivatives as thyroid receptor ligands
US6344481B1 (en) * 1999-03-01 2002-02-05 Pfizer Inc. Thyromimetic antiobesity agents
US6716452B1 (en) * 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US6627660B1 (en) 1999-11-16 2003-09-30 New River Pharmaceuticals Inc. Stabilized thyroxine compounds
EP1127882A1 (en) * 2000-01-25 2001-08-29 Pfizer Products Inc. Tetrazole compounds as thyroid receptor ligands
CA2403806A1 (en) * 2000-03-23 2002-09-20 Bayer Aktiengesellschaft Indoles for treating diseases that can be treated using thyroid hormones
IL151376A0 (en) * 2000-03-31 2003-04-10 Pfizer Prod Inc Malonamic acids and derivatives thereof as thyroid receptor ligands
US6664291B2 (en) 2000-03-31 2003-12-16 Pfizer, Inc. Malonamic acids and derivatives thereof as thyroid receptor ligands
US6620830B2 (en) * 2000-04-21 2003-09-16 Pfizer, Inc. Thyroid receptor ligands
DE10024939A1 (de) * 2000-05-19 2001-11-29 Bayer Ag Neue Diphenylmethanderivate für Arzneimittel
DE10038007A1 (de) 2000-08-04 2002-02-14 Bayer Ag Neue Amino-und Amido-Diphenylether für Arzneimittel
DE10046029A1 (de) 2000-09-18 2002-03-28 Bayer Ag Indazole
US8394813B2 (en) 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
CA2433100A1 (en) 2000-12-27 2002-07-04 Helmut Haning Indole derivatives as ligands of thyroid receptors
US6777442B2 (en) 2001-03-12 2004-08-17 Bayer Aktiengesellschaft Diphenyl derivatives
US7169752B2 (en) 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
IL159006A0 (en) 2001-08-24 2004-05-12 Karobio Ab Phenoxy-phenyl derivatives and pharmaceutical compositions containing the same
GB0120691D0 (en) * 2001-08-24 2001-10-17 Karobio Ab Novel Compounds
DE60208132T2 (de) 2001-09-26 2006-07-20 Pfizer Products Inc., Groton Indolcaroboxylsäure als Thyroidrezeptor-Liganden
KR20050119652A (ko) 2003-03-24 2005-12-21 에프. 호프만-라 로슈 아게 역전사 효소 저해제로서의 벤질-피리다진온
EP1689383B1 (en) * 2003-11-19 2012-10-31 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
US8779175B2 (en) 2004-10-25 2014-07-15 Synthonics, Inc. Coordination complexes, pharmaceutical solutions comprising coordination complexes, and methods of treating patients
US20060141054A1 (en) * 2004-10-25 2006-06-29 Thomas Piccariello Metal coordinated compositions
AU2005308575A1 (en) * 2004-11-23 2006-06-01 Warner-Lambert Company Llc 7-(2h-pyrazol-3-yl)-3, 5-dihyroxy-heptanoic acid derivatives as HMG Co-A reductase inhibitors for the treatment of lipidemia
JP4810862B2 (ja) * 2005-04-11 2011-11-09 Ｊｓｒ株式会社 オニウム塩、それを用いた感放射線性酸発生剤及びポジ型感放射線性樹脂組成物
US20090028925A1 (en) * 2005-05-26 2009-01-29 Erion Mark D Novel Phosphinic Acid-Containing Thyromimetics
CA2606499C (en) 2005-05-26 2017-06-13 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
CN101291640A (zh) * 2005-06-24 2008-10-22 托马斯·拉文 甲状腺素化合物用于人体烧伤和脂肪沉积的治疗
HRP20100633T1 (hr) * 2005-07-21 2011-01-31 F. Hoffmann - La Roche Ag Derivati piridazinona kao agonisti receptora tiroidnih hormona
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US8383660B2 (en) 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives
WO2008019306A2 (en) * 2006-08-04 2008-02-14 Decode Genetics Ehf Aryl amino acid derivatives as inhibitors of lta4h (leukotriene a4 hydrolase) for treating inflammation
JP5498168B2 (ja) 2006-12-01 2014-05-21 ブリストル−マイヤーズ スクイブ カンパニー アテローム性動脈硬化および循環器疾患の治療のためのｃｅｔｐ阻害剤としてのｎ−（（３−ベンジル）−２，２−（ビス−フェニル）−プロパン−１−アミン誘導体
US8076334B2 (en) 2007-09-20 2011-12-13 Hoffmann-La Roche Inc. Prodrugs of thyroid hormone analogs
CA3044059A1 (en) 2016-11-21 2018-05-24 Viking Therapeutics, Inc. Method of treating glycogen storage disease
EA201992703A1 (ru) 2017-06-05 2020-04-15 Вайкинг Терапьютикс, Инк. Композиции для лечения фиброза
CA3094167A1 (en) 2018-03-22 2019-09-26 Viking Therapeutics, Inc. Crystalline forms and methods of producing crystalline forms of a compound
WO2020117962A1 (en) 2018-12-05 2020-06-11 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR289M (fr) * 1959-01-05 1961-02-24 Glaxo Lab Ltd Médicament utilisable dans le traitement de l'hypercholestérolémie et des états apparentés, a base de dérivés de la thyronine.
US3017428A (en) * 1959-08-18 1962-01-16 Univ California Antihypercholesterolemic thyronine derivatives
DE1200832B (de) * 1961-12-05 1965-09-16 Smith Kline French Lab Verfahren zur Herstellung von 3, 5-Dijodthyroninderivaten
US3149153A (en) * 1961-12-05 1964-09-15 Smith Kline French Lab 3'-substituted-3, 5-diiodothyronine and salts thereof
US3287396A (en) * 1963-01-11 1966-11-22 Smith Kline French Lab Phenyldesoxythyronines
GB1047082A (en) * 1963-02-01 1966-11-02 Pfizer & Co C Thyronine derivatives
US3477954A (en) * 1966-06-29 1969-11-11 Armour Pharma Phosphonium iodide complexes of thyroxine,methods of preparing same,and methods of preparing 3,5,3'-l-triiodothyronine therefrom
GB8501372D0 (en) * 1985-01-18 1985-02-20 Smith Kline French Lab Chemical compounds

Also Published As

Publication number Publication date
JPH07103070B2 (ja) 1995-11-08
FI860229A7 (fi) 1986-07-19
DK18586A (da) 1986-07-19
NO860159L (no) 1986-07-21
CN1010310B (zh) 1990-11-07
ES8800157A1 (es) 1987-11-01
PT81844B (pt) 1988-05-27
US4766121A (en) 1988-08-23
HU194807B (en) 1988-03-28
PH22691A (en) 1988-11-14
IE860143L (en) 1986-07-18
EP0188351A3 (en) 1989-03-15
IE58867B1 (en) 1993-11-17
CN86100894A (zh) 1986-09-03
DK18586D0 (da) 1986-01-15
GB8501372D0 (en) 1985-02-20
PT81844A (en) 1986-02-01
KR860005788A (ko) 1986-08-13
EP0188351A2 (en) 1986-07-23
KR930011302B1 (ko) 1993-11-29
DE3678000D1 (de) 1991-04-18
GR860122B (en) 1986-05-19
ATE61581T1 (de) 1991-03-15
HUT40401A (en) 1986-12-28
IL77605A (en) 1990-02-09
CA1319148C (en) 1993-06-15
DK164592C (da) 1992-12-07
IL77605A0 (en) 1986-07-31
US4826876A (en) 1989-05-02
AU577917B2 (en) 1988-10-06
US4910305A (en) 1990-03-20
EP0188351B1 (en) 1991-03-13
NZ214843A (en) 1989-02-24
ZA86319B (en) 1986-08-27
AU5221986A (en) 1986-07-24
ZW886A1 (en) 1987-05-13
JPS61167643A (ja) 1986-07-29
FI860229A0 (fi) 1986-01-17
DK164592B (da) 1992-07-20
JO1439B1 (en) 1988-03-10

Similar Documents

Publication Publication Date Title
KR860005788A (ko) 티로닌 유도체의 제조방법
DE3862928D1 (de) Chinazolinon-derivate.
DE68919010D1 (de) Purinverbindungen, Verfahren zu ihrer Herstellung und pharmazeutische Präparate.
ES553936A0 (es) Un procedimiento para la preparacion de nuevas n-((4-piperidinil)alquil)oxazol y tiazolaminas condensadas biciclicas sustituidas
ES2111352T3 (es) Uso de diester fosfato para el tratamiento de enfermedades retinianas.
DK454685A (da) Pyrazolo(3,4-b)-pyridinamider
ATE39482T1 (de) N-(1-ethyl-2-pyrrolidinylmethyl)-benzamidderivate, verfahren und zwischenprodukte zu ihrer herstellung und sie enthaltende pharmazeutische zubereitungen.
ES2109216T3 (es) Un procedimiento para la preparacion de una composicion farmaceutica con actividad relajante muscular de accion central.
ES534859A0 (es) Procedimiento para la obtencion de derivados de 1-(4'-alquilsulfonilfenil)-2-amino-1,3-propandiol n-substituidos
FR2597097B1 (fr) Derives de benzothiazepine-1, 5, leur preparation et leur application en therapeutique
ES557149A0 (es) Un procedimiento para la preparacion de derivados peptidicos de histidinilprolinamida.
ES534858A0 (es) Procedimiento para la obtencion de derivados de 1-(4'-alquiltiofenil)-2-amino-1,3-propandiol
FR2593180B1 (fr) Derives d'acylaminomethyl-1 imidazo (1,2-a)quinoleines, leur preparation et leur application en therapeutique
DK282786D0 (da) Ergolinderivater, fremgangsmaade til fremstilling deraf og forbindelser til anvendelse som mellemprodukter ved fremgangsmaaden samtfarmaceutiske praeparater
SE8305362D0 (sv) Novel substituted phenylazacycloalkanes, processes for preparation and pharmaceutical preparations for such compounds
ATE23161T1 (de) 3-deazaguanin-sulfonsaeuresalze.

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 20070903